Hypodermoclysis (HDC) for symptom control vs. the Edmonton Injector (EI).
Hypodermoclysis (HDC) is a well-known method of providing symptom control in terminally ill patients. In this article we make reference to two previous reports describing our use of HDC and a new method of subcutaneous narcotic delivery called the Edmonton Injector (EI). The rationale for using HDC mainly for rehydration and the EI when subcutaneous narcotics are needed is explored. The controversy surrounding the treatment of dehydration in the terminally ill is examined. Finally, the advantages on our palliative care unit of the convenience, increased flexibility, and cost and time saving of these two treatment methods are discussed.
Fainsinger
R L
RL
Edmonton General Hospital, Alberta, Canada.
Bruera
E
E
D003362:Cost-Benefit Analysis; D005069:Evaluation Studies as Topic; D005440:Fluid Therapy / Q000295:instrumentation; D006801:Humans; D007260:Infusion Pumps / Q000191:economics / Q000592:standards*; D007263:Infusions, Parenteral / Q000295:instrumentation*; D007279:Injections, Subcutaneous / Q000295:instrumentation*; D009294:Narcotics / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D013727:Terminal Care / Q000379:methods*
D009294:Narcotics